July 2014 FDA Recall Drug by Mylan Institutional, Inc. (d.b.a. Udl Laboratories) (D-1435-2014 - Failed Impurities/Degradation Specifications)

This Class III drug recall was voluntarily initiated by Mylan Institutional, Inc. (d.b.a. Udl Laboratories) on July 3, 2014 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1435-2014

Reason for Recall
Failed Impurities/Degradation Specifications: High out-of-specification results for a related compound obtained during routine stability testing.
Initiated
07-03-2014
Reported
07-23-2014
Quantity
1,184 cartons

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Nationwide, Puerto Rico, and Guam.
Diltiazem HCl Extended-release Capsules, USP, 120 mg, packaged in 80 Capsules (8 x 10) blister cards per carton, Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 51079-947-08.

Batch or Lot Expiration Information

Lot# : 3045659, 3048256, Exp 07/14